Business
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencingMENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a cli
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"image","alt":"PacBio","displaySize":"","headline":null,"caption":"PacBio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nO_Xed3UYAG.Z8cezVsIzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca3b97d5b827c8cc2602900e245a01c9","width":300,"height":263}},"lazy":false},{"type":"text","content":"Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing","length":155,"tagName":"p"},{"type":"text","content":"MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors.","length":242,"tagName":"p"},{"type":"text","content":"Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He led the company from inception through significant capital formation, strategic partnerships, and a successful public listing, establishing Recursion as a leader at the intersection of computation and biology.","length":705,"tagName":"p"},{"type":"text","content":"“Dr. Gibson has demonstrated how AI, automation, and high-dimensional biological data can be combined to transform scientific discovery,” said Christian Henry, Chief Executive Officer of PacBio. “As HiFi sequencing datasets grow in scale, the ability to leverage the full power of the HiFi genome through advanced analytics is becoming increasingly strategic. Dr. Gibson’s experience building and scaling an AI-native life sciences company will directly support our long-term vision of integrating sequencing, computation, and data-driven discovery.”","length":550,"tagName":"p"},{"type":"text","...